FierceBiotech Apr 21, 2026 Gilead loosens ties to Arcus after TIGIT dream finally ends in phase 3 failure
FierceBiotech Apr 21, 2026 With $50M from Flagship Pioneering, Serif strives to write new chapter for DNA medicines
FierceBiotech Apr 21, 2026 Replimmune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection
FierceBiotech Apr 20, 2026 AACR: Endeavoring to go global, Zai Lab offers reality check on China’s biotech ascent
FierceBiotech Apr 20, 2026 Novo readies SCD drug from $1.1B Forma buyout for approval push after phase 3 win
FierceBiotech Apr 20, 2026 Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B
FierceBiotech Apr 20, 2026 Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody
FierceBiotech Apr 20, 2026 Odyssey charts fresh voyage to public markets after abandoning IPO plans last year
FierceBiotech Apr 20, 2026 AstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win
FierceBiotech Apr 20, 2026 How WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients
FierceBiotech Apr 20, 2026 FDA celebrates progress to end animal testing but experts warn there’s still a long way to go
FierceBiotech Apr 20, 2026 AACR: Former Genentech leader engineers startup with vision for ‘smart’ cancer drugs
FierceBiotech Apr 18, 2026 AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’
FierceBiotech Apr 17, 2026 UCB pays $650M+ for Neurona, marking 'strategic expansion' into regenerative medicine